A Phase 3b, Multicenter, Randomized, Open-Label Study of Risankizumab Compared to Vedolizumab for the Treatment of Adult Subjects With Moderate to Severe Ulcerative Colitis Who are Naïve to Targeted Therapies

drug protocol number

M25-540

drug sponsor

AbbVie

drug study

Risankizumab

drug trial site

King Khalid University Hospital (Riyadh), King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City, National Guard Health Affairs (Riyadh)

drug status

Ongoing

drug phase